Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Mar. 29, 5:54 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
Slide #66. Salix Pharmaceuticals, Ltd. — Santarus
Acquirer: |
Salix Pharmaceuticals, Ltd. (SLXP) |
Acquiree: |
Santarus (SNTS) |
Details: |
Salix Pharmaceuticals, Ltd., and Santarus, Inc. announced today that the companies have entered into a merger agreement where Salix will acquire all of the outstanding stock of Santarus for $32 in cash per share, for a total value of approximately $2.6 billion. Covington & Burling LLP is advising Salix on both the acquisition and financing aspects of the transaction. |
Salix Pharmaceuticals is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. Co.'s products include among others, XIFAXAN550® (rifaximin) Tablets, indicated for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years and older; XIFAXAN (rifaximin) tablets, indicated for the treatment of patients 12 years of age and older with travelers' diarrhea; and APRISO® (mesalamine) extended-release capsules, indicated for the maintenance of remission of ulcerative colitis.
Open the SLXP Page at The Online Investor »
Salix Pharmaceuticals is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. Co.'s products include among others, XIFAXAN550® (rifaximin) Tablets, indicated for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years and older; XIFAXAN (rifaximin) tablets, indicated for the treatment of patients 12 years of age and older with travelers' diarrhea; and APRISO® (mesalamine) extended-release capsules, indicated for the maintenance of remission of ulcerative colitis.
Open the SNTS Page at The Online Investor »